摘要
目的观察神经生长因子（NGF）对重型颅脑损伤患者血浆肌酸激酶同工酶BB（CK-BB）动态变化的影响以及临床疗效。方法将上海交通大学医学院附属第三人民医院神经外科自2006年8月至2008年8月收治的80例重型颅脑损伤患者（GCS≤8分）分成2组．对照组40例采用常规治疗，试验组40例在常规治疗的基础上加用NGF治疗。观察2组患者血浆CK-BB变化，并于伤后6个月按GOS预后评分评定预后，同时比较2组患者的清醒率及清醒时间。结果治疗后第1、5、10、20、28天试验组患者血浆CK-BB均明显低于对照组，差异有统计学意义（P〈0．05）。试验组预后情况明显优于对照组，差异有统计学意义（P〈0．05）。试验组治疗后1个月清醒32例，对照组18例，差异有统计学意义（P〈0．05）。试验组清醒时间为（12．43±6．25）d，对照组为（15．96±7．58）d．差异有统计学意义（P〈0．05）。结论NGF能有效降低重型颅脑损伤患者血浆CK-BB的水平，促进重型颅脑损伤患者的清醒，改善预后。
Objective To investigate the influence of nerve growth factor （NGF） on the level of plasma creatine kinase BB （CK-BB） and its clinical effect in patients with severe craniocerebral trauma. Methods Eighty patients with severe craniocerebral trauma （GCS ≤ 8） were randomly assigned to NGF-treated （n=40） and control （n=40） groups. Conventional therapy was performed on these patients and NGF was added into the NGF-treated group. The level of plasma CK-BB in these patients was measured, the clinical prognosis of the patients was evaluated based on the GOS scores 6 months after severe craniocerebral trauma; the condition of regained consciousness was compared between the 2 groups. Results Plasma CK-BB in the NGF-treated group was significantly lower than that in the control group （P〈0.05）; the recovery rate in the NGF-treated group （24/40） was significantly higher than that in the control group （11/40）; the consciousness regained within 1 month was found in 32 patients in the NGF-treated group but only 18 of that was noted in the control group （P〈0.05）; NGF-treated group （12.43±6.25） showed a significantly shorter time that consciousness was regained as compared with the control group （15.96±7.58）. Conclusion NGF can decrease the level of plasma CK-BB, shorten coma time and improve life quality in patients with severe craniocerebral trauma. Application ofNGF, a safe and effective treatment method, provides a new potential therapeutic strategy for patients with CNSinjury.
出处
《中华神经医学杂志》
CAS
CSCD
北大核心
2010年第2期190-192,195,共4页
Chinese Journal of Neuromedicine
关键词
神经生长因子
颅脑损伤
昏迷
Nerve growth factor
Craniocerebral trauma
Coma
